Rebecca Chambers Sells 964 Shares of Inari Medical, Inc. (NASDAQ:NARI) Stock

Inari Medical, Inc. (NASDAQ:NARI - Get Free Report) Director Rebecca Chambers sold 964 shares of the business's stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $45.39, for a total transaction of $43,755.96. Following the transaction, the director now owns 9,944 shares in the company, valued at approximately $451,358.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Inari Medical Price Performance

Shares of NARI stock traded down $0.41 during trading hours on Tuesday, reaching $45.72. 440,968 shares of the company were exchanged, compared to its average volume of 1,145,637. Inari Medical, Inc. has a fifty-two week low of $36.73 and a fifty-two week high of $71.85. The stock's fifty day moving average is $42.57 and its two-hundred day moving average is $52.63. The company has a market cap of $2.66 billion, a price-to-earnings ratio of -111.51 and a beta of 0.93.

Inari Medical (NASDAQ:NARI - Get Free Report) last announced its earnings results on Tuesday, April 30th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.15). The company had revenue of $143.19 million for the quarter, compared to analyst estimates of $138.32 million. Inari Medical had a negative return on equity of 1.65% and a negative net margin of 4.54%. On average, research analysts anticipate that Inari Medical, Inc. will post -0.41 earnings per share for the current year.

Institutional Investors Weigh In On Inari Medical

Institutional investors and hedge funds have recently modified their holdings of the business. Fifth Third Bancorp raised its stake in shares of Inari Medical by 54.3% during the third quarter. Fifth Third Bancorp now owns 486 shares of the company's stock worth $32,000 after buying an additional 171 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Inari Medical during the first quarter worth approximately $30,000. Benjamin F. Edwards & Company Inc. raised its stake in shares of Inari Medical by 27.4% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 1,098 shares of the company's stock worth $71,000 after buying an additional 236 shares during the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Inari Medical by 139.7% during the third quarter. Nisa Investment Advisors LLC now owns 1,189 shares of the company's stock worth $78,000 after buying an additional 693 shares during the last quarter. Finally, Covestor Ltd raised its stake in shares of Inari Medical by 30.2% during the first quarter. Covestor Ltd now owns 1,619 shares of the company's stock worth $78,000 after buying an additional 376 shares during the last quarter. 90.98% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

NARI has been the topic of a number of recent analyst reports. Wells Fargo & Company reduced their price target on shares of Inari Medical from $100.00 to $84.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 1st. Truist Financial reduced their price target on shares of Inari Medical from $61.00 to $52.00 and set a "hold" rating on the stock in a research report on Friday, March 22nd. Piper Sandler reduced their price target on shares of Inari Medical from $55.00 to $50.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 1st. Needham & Company LLC reduced their price target on shares of Inari Medical from $72.00 to $57.00 and set a "buy" rating on the stock in a research report on Wednesday, May 1st. Finally, Canaccord Genuity Group reduced their price target on shares of Inari Medical from $75.00 to $55.00 and set a "buy" rating on the stock in a research report on Wednesday, May 1st. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $65.71.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.